B型肝炎ワクチンの世界市場機会分析

◆英語タイトル:MarketVIEW: Hepatitis B virus vaccines - Global vaccine commercial opportunity assessment
◆商品コード:MR-VAMV033
◆発行会社(リサーチ会社):VacZine Analytics
◆発行日:2015年3月
◆ページ数:74(PDFの場合)
◆レポート形式:英語 / PDF or Excel
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Executive Presentation (PDF)GBP3,250 ⇒換算¥481,000見積依頼/購入/質問フォーム
Forecast Model (Excel)GBP3,250 ⇒換算¥481,000見積依頼/購入/質問フォーム
PDF+ExcelGBP6,500 ⇒換算¥962,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。VacZine Analytics社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、B型肝炎ワクチンの世界市場機会について調査・分析し、B型肝炎の概要、疫学トレンド、リスク要因、B型肝炎の診断、治療戦略、研究開発動向、ワクチン接種へのアプローチ、ワクチン開発における重要要素、ターゲット製品プロファイル、商用化/市場予測モデリング・シナリオ、価格分析、B型肝炎ワクチンの市場規模予測結果(金額及びボリューム)などの情報をお届けいたします。
【レポートの概要】

Hepatitis B virus (HBV) is transmitted by exposure to infectious blood or body fluids by percutaneous or mucosal means. Transmission occurs usually amongst adults exhibiting risk behaviours e.g. IDUs, MSM and heterosexuals with multiple partners although vertical transmission can occur from mother to child at birth. The HBV virus is more infectious than HIV and can cause chronic infection, resulting in cirrhosis of the liver, liver cancer, liver failure, and death. It is estimated that 2 billion people worldwide have been infected with the virus and about 600 000 people die every year due to the consequences of hepatitis B (WHO Figures).

This MarketVIEW is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of Hepatitis B Virus (HBV) adult vaccines across major Western markets until 2030. The model contains value ($ m) and volume (mio doses) predictions per product type along with timeframe, pricing and penetration estimates for all adult risk groups and infants vaccination (where policy in place). The product also includes two different scenarios for the potential penetration of Dynavax’s new HBV vaccine Heplisav into US and EU markets and giving estimates of potential revenues to 2030.

*** THIS PRODUCT IS A EXECUTIVE PRESENTATION + 3 MODELS

【レポートの目次】

※レポート紹介PDF⇒ http://www.vaczine-analytics.com/VAMV033_TOC_150302.pdf

****This product is composed of two models and summary presentation
Author’s note
Contents
Executive Summary
Commercial model: outputs
General summary of changes from versions 2013 to 2015
HBV vaccines: revenues by vaccine type to 2030 (Western) ($m)
HBV vaccines: revenues by vaccine type to 2030 (per country) ($m)
Monovalent HBV vaccines: revenues to 2030 (per country) ($m)
Monovalent HBV vaccines: revenues to 2030 (per risk group) ($m)
Heplisav: market revenues to 2030 ($m) – SCENARIO 1
Heplisav: market revenues to 2030 ($m) – SCENARIO 2
Hepatitis B virus background: Epidemiology update
HBV: epidemiology summary
HBV: global epidemiology
HBV: global prevalence of chronic infection
Characteristics of hepatitis B in US
US: HBV incident cases and risk exposures (2012)
Reported number of acute HBV cases – US, 2000-2012
US: HBV incident cases and risk exposures 1980-2010
Acute HBV reports by risk exposure (US, 2012)
US – HBV surface antigen positivity by state, 2009
Europe: HBV epidemiology
Europe: number of reported HBV cases in the EU/EEA, 2012
Number and rates of HBV reported cases, EU/EEA, 2009-2012
Europe: HBV cases – by age group & gender EU/EEA (2011)
Hepatitis B virus background: vaccines
Reimbursement polices: per major risk group/country
Vaccine market share split per country
At risk populations per country
HBV vaccine coverage by country
HBV background
HBV epidemiology summary
HBV global epidemiology
US: incident cases and risk exposures
National HBV vaccine policies
National HBV vaccine policies: forecast immunity to 2030
Hepatitis B vaccines: major suppliers
Hepatitis B vaccines: dosing/administration schedules
GSK Biologicals: hepatitis vaccine sales, 2005-14
Merck & Co (SPMSD): hepatitis vaccine sales, 2005-14
Engerix B: SWOT
Recombivax-HB: SWOT
New Hepatitis B vaccines: Heplisav (Dynavax)
Dynavax: Heplisav – background
Heplisav: Phase III data
Heplisav: seroprotection rates (HBV-16) study
Heplisav: immunogenicity in diabetic subjects
Heplisav: FDA – Complete Response Letter
Heplisav: HBV-23 study
Heplisav: approval timeframe (US)
HBV vaccines: commercial model: key assumptions and methodology
Overview of modeling strategy
Target populations modelled
HBV vaccines: target populations (US, 2015) (000s)
Healthcare workers: modeling strategy
Travelers: modeling strategy
Diabetics: modeling strategy, US
Infants: modeling strategy
Other “at risk” populations: modelling strategy
Summary of population changes from version 2013 – 2015
Pricing and reimbursement
Pricing assumptions
Market share split by country: by vaccine type
At risk populations by country
HBV vaccine coverage by country
HBV vaccination in US diabetics 2010-2013
Heplisav: market share/pricing estimates
Heplisav: expected commercial value US
Appendix I: Actual reported and estimated sales data
Hepatitis vaccines sales data
Bibliography
About VacZine Analytics
Disclaimer

*** PAGES: ~74 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

[Contents – Vaccine demand models (MS Excel-based)]
Title sheet
CHARTS – VALUE
CHARTS – VOLUME
Heplisav sales forecast
Country value summary
Value adults (all)
Value adults (monovalent)
Value (Twinrix)
Volume
Adult worksheets 
US (adults)
Canada (adults)
Australia (adults)
France (adults)
Germany (adults)
Italy (adults)
Spain (adults)
UK (adults)
Spain (adults)
Adult worksheets 
US (infants)
Canada (infants)
Australia (infants)
Europe universal (infants)
Europe at risk (infants)
Source material 
Births
Total populations
18-49 yrs
Global price summary
At risk variables
Public/private split
Monovalent combi split
ESRD incidence forecast
ESRD incident cases 2014 report
ESRD incidence rate 2014 report
Trips to HBV endemic countries
Travel market variables
HBV cases US
HBV cases US by risk group
HBV cases US
Diabetes
Pneumo vaccine coverage
Sales data
Sales charts
Back page

*** Worksheets = 65 interconnected

【レポートのキーワード】

B型肝炎、ワクチン、治療薬

【リサーチ方法】

VacZine Analytics has closely monitored all significant source material pertaining Hepatitis B Virus (HBV) epidemiology, disease indications and target groups. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by VacZine Analytics in the field of viral pathogens has also been utilised.

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ B型肝炎ワクチンの世界市場機会分析(MarketVIEW: Hepatitis B virus vaccines - Global vaccine commercial opportunity assessment)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆